Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Support Care Cancer

Amgen Inc., Thousand Oaks, CA, USA.

Published: January 2016

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828362	PMC
http://dx.doi.org/10.1007/s00520-015-2985-1	DOI Listing

Publication Analysis

erratum safety

safety long-term

long-term denosumab

denosumab therapy

therapy open

open label

label extension

extension phase

phase phase

phase studies

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!